Genprex, Inc. announced that the China National Intellectual Property Administration has granted Genprex China Patent No:201780 076886.X. The broad patent covers the use of Genprex's lead drug candidate, REQORSA(R) Immunogene Therapy, in combination with PD1 antibodies through 2037. In 2022, Genprex received a U.S. patent granting protection for the combination of REQORSA with PD1 antibodies for the treatment of cancer. In 2021, Genprex received U.S. Food and Drug Administration's (FDA) Fast Track Designation for treatment of the Acclaim-2 patient population.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.44 USD | -4.31% | +2.09% | -73.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-73.48% | 5.12M | |
+9.58% | 115B | |
+12.41% | 107B | |
-12.38% | 22.31B | |
-3.76% | 21.6B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B | |
-24.50% | 8.28B |
- Stock Market
- Equities
- GNPX Stock
- News Genprex, Inc.
- Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers